CHITOSE Group

CHITOSE Group is a private biotechnology group headquartered in Singapore with major operations in Japan and Southeast Asia, focused on building bio-based industrial and healthcare businesses. Through its core operating company, Chitose Laboratory, the group develops cell lines, microbial and algal cultivation technologies, AI-enabled bioprocess optimization, and commercialization support across pharmaceuticals, agriculture, food, chemicals, and energy. In healthcare and biopharma, CHITOSE offers mammalian cell line technologies including its CHO-MK platform for antibody and recombinant protein manufacturing and its HAT cell line for adeno-associated virus vector production in gene therapy. The company also operates large-scale microalgae infrastructure, including the C4 production facility in Sarawak, and is advancing the MATSURI initiative to scale algae-based circular manufacturing. Overall, CHITOSE is best understood as a bioeconomy platform company with meaningful healthcare relevance through biomanufacturing-enabling technologies rather than as a traditional therapeutic drug developer.